You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨派格生物醫藥-B首日上市破發,一度大跌28%
派格生物醫藥-B(2565.HK)今日首日在港掛牌上市,盤初一度跳水跌28%,報11.22港元,首日上市即破發。該股IPO價格爲15.6港元。成立於2008年的派格生物是一家專注於自主研究及開發慢性病創新療法(主要爲肽和小分子藥物)的生物技術公司,重點關代謝紊亂領域。招股章程顯示,派格生物已自主開發一款核心產品及其他五款候選產品,以把握2型糖尿病(T2DM)、肥胖症、非酒精性脂肪性肝炎(NASH)、阿片類藥物引起的便祕(OIC,使用阿片類藥物引起的胃腸道疾病)及先天性高胰島素血癥(一種罕見的內分泌疾病,患者持續出現低血糖症)等常見慢病及代謝疾病的市場機會。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account